Ambio Announces US FDA Approval of a Generic Version of Forteo® (Teriparatide Injection) for Its Partner Apotex

Contributed by: Business Wire

Logo

Tags

Science

Biotechnology

Research

Pharmaceutical

Managed Care

General Health

Health

FDA

Apotex

More Like This

Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function

Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome

PR Newswire associated0

Bone Health: Biocon Biologics Receives Positive CHMP Opinions for Biosimilar Denosumab in Europe

Business Wire associated0

Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics

GlobeNewswire associated0

Adalvo Secures First EU Generic Approval for Liraglutide Pre-Filled Pen

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel

Sofinnova Partners Portfolio Company Amolyt Pharma to be Acquired by AstraZeneca

Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars